As the COVID-19 pandemic kept many kids out of the classroom for more than a year-and-a-half, students around the country are venturing from their rooms at home to First Period home room to rejoin classmates.
And parents understandably could be feeling the anxiety of separation.
How to cut that uncertainty? Preparation.
We know that just because they'll be out of sight doesn't mean they'll be out of mind. Our technologies to help ease your mental load and provide more control to parents heading into the school year.
With the Delta variant of COVID-19 dominating — a strain that's demonstrating it's highly transmissible, more so than even the common cold, chicken pox or the flu — BinaxNOW rapid antigen testing can quickly and reliably let parents know their children's COVID status before they return to the classroom.
And for parents and caregivers of children over 4 using the FreeStyle Libre 2 continuous glucose monitoring system to manage their diabetes, apps including the FreeStyle Libre 2 iOS app and Libre LinkUp1 app can share data collected by the FreeStyle Libre 2 sensor so you can see how your child's glucose levels are doing during the school day.
Children returning to classrooms can feel like the new "distance learning," with an uncomfortable emphasis on the distance between parents and kids. We want to help restore your confidence as they step through the schoolhouse door.
Our technologies are designed to be accessible and affordable to help alleviate those worries so you have time for more pressing concerns, from their grades and college entrance exams to making the team and being cast in the school play.
1The LibreLinkUp app is only compatible with certain mobile device and operating systems. Please check www.librelinkup.com for more information about device compatibility before using the app.
IMPORTANT SAFETY INFORMATION
BINAXNOW EMERGENCY USE AUTHORIZATIONS
FREESTYLE LIBRE 2
Failure to use FreeStyle Libre 2 system as instructed in labeling may result in missing a severe low or high glucose event and/or making a treatment decision, resulting in injury. If glucose alarms and readings do not match symptoms or expectations, use a fingerstick value from a blood glucose meter for treatment decisions. Seek medical attention when appropriate or contact Abbott at 855-632-8658 or FreeStyleLibre.us for safety info.
BINAXNOW EMERGENCY USE AUTHORIZATIONS
The BinaxNOW™ COVID-19 Antigen Self Test is a lateral flow immunoassay intended for the qualitative detection of nucleocapsid protein antigen from SARS-CoV-2 from individuals with or without symptoms or other epidemiological reasons to suspect COVID-19 infection when tested twice over three days with at least 36 hours between tests. This test is authorized for non-prescription home use with self-collected direct anterior nasal (nares) swab samples from individuals aged 15 years or older or adult collected anterior nasal swab samples from individuals aged two years or older.
The BinaxNOW COVID-19 Ag 2 Card is a lateral flow immunoassay intended for the qualitative detection of nucleocapsid protein antigen from SARS-CoV-2 in direct anterior nasal (nares) swab samples from COVID-19 symptomatic individuals tested twice over three days with at least 36 hours between tests within the first seven days of symptom onset.
This test is authorized for use with direct anterior nasal (nares) swab samples from individuals without symptoms or other epidemiological reasons to suspect COVID-19, when tested twice over three days with at least 36 hours between tests. Testing is limited to laboratories certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA), 42 U.S.C. §263a, that meet the requirements to perform moderate, high, or waived complexity tests. This test is authorized for use at the Point of Care (POC), i.e., in patient care settings operating under a CLIA Certificate of Waiver, Certificate of Compliance, or Certificate of Accreditation.
The BinaxNOW COVID-19 Ag tests have not been FDA cleared or approved. They have been authorized by the FDA under an emergency use authorization. The tests have been authorized only for the detection of proteins from SARS-CoV-2, not for any other viruses or pathogens, and are only authorized for the duration of the declaration that circumstances exist justifying the authorization of emergency use of in vitro diagnostics for detection and/or diagnosis of COVID-19 under Section 564(b)(1) of the Federal Food, Drug and Cosmetic Act, 21 U.S.C. § 360bbb-3(b)(1), unless the declaration is terminated or authorization is revoked sooner.
KEYWORDS: NYSE:ABT, COVID-19, Abbott, news, BinaxNOW, rapid tests, COVID schools